APS is recognized as an acquired autoimmune thrombophilia, characterized by recurrent thrombotic events. It has been shown that APLA can disrupt natural anticoagulant pathways, such as the protein C system, and upregulate tissue factor expression, thereby further promoting coagulation. Here, F3 is linked to autoimmune polyendocrinopathy.